Plaintiff
1 case as plaintiff.
Let me verify the litigation context.
Overview. Molina Healthcare, Inc. (NYSE: MOH) is a publicly traded managed-care organization headquartered at 200 Oceangate, Long Beach, California. It was founded in 1980 by Dr. C. David Molina as a clinic serving low-income families in Southern California, reincorporated in Delaware in 2002, and went public in July 2003. It is a Fortune 500 company with roughly 19,000 employees, trailing-twelve-month revenue of about $44–45 billion (FY2025: ~$45.4B), and a market capitalization in the $10–13 billion range as of 2026. It is not a subsidiary; it is the parent of numerous state-licensed health-plan subsidiaries.
Operations. Molina is a pure-play government-sponsored insurer, not a patent holder or licensor. It operates four reportable segments: Medicaid (core business, with contracts with state agencies for families, CHIP, aged/blind/disabled, long-term services and supports, foster care and behavioral health), Medicare (Medicare Advantage and Dual Eligible Special Needs Plans), Marketplace (ACA individual and family exchange plans), and Other. As of December 31, 2025 it served roughly 5.5 million members across 21 states, arranging care through contracted provider networks rather than delivering care directly at scale.
Litigation posture. The case data shows one tracked matter, as plaintiff and zero as defendant, which is uncharacteristic of a patent litigant and consistent with an operating company that does not assert patents. The single suit is an antitrust action, not a patent-infringement suit: Molina is a payer suing a drug manufacturer over the manufacturer's patent-and-settlement conduct.
Notable case. Molina Healthcare, Inc. v. Celgene Corp., No. 2:22-cv-04561 (D.N.J., filed July 13, 2022), was consolidated into In re Revlimid & Thalomid Purchaser Antitrust Litigation (No. 19-7532, D.N.J.). Molina alleged Celgene and Bristol-Myers Squibb monopolized the markets for Revlimid (lenalidomide) and Thalomid (thalidomide) through fraudulently obtained patents, sham infringement suits, REMS-related sample refusals, and reverse-payment settlements with generics, seeking damages and injunctive relief under state antitrust and unfair-practices laws. In June 2024 the court granted the defendants' motions and dismissed the insurer plaintiffs' complaints in their entirety.
Sources: Molina Healthcare annual report/10-K (SEC); Fortune; StockAnalysis; PitchBook; CourtListener/Justia dockets (D.N.J. 2:22-cv-04561).
Antitrust action in which the '428 patent is cited as part of the challenged Celgene patent portfolio; Molina Healthcare sued Celgene in D.N.J. Status is generally pending/consolidated.